Replimune Group (NASDAQ:REPL) Shares Up 5.1% – What’s Next?

Shares of Replimune Group, Inc. (NASDAQ:REPL) rose 5.1% during trading on Tuesday. The stock traded as high as $13.26 and last traded at $13.1970. 1,085,693 shares were traded during mid-day trading, a decline of 76% from the average session volume of 4,544,294 shares. The stock had previously closed at $12.56.

Analyst Upgrades and Downgrades

REPL has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a research note on Tuesday, June 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Replimune Group Stock Performance

The company has a 50-day moving average price of $13.13 and a 200-day moving average price of $9.29. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -4.20 and a beta of 0.94.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, equities research analysts forecast that Replimune Group, Inc. will post -2.82 earnings per share for the current year.

Insider Activity

In other news, CAO Andrew Schwendenman sold 7,632 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the sale, the chief accounting officer owned 99,425 shares in the company, valued at $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the sale, the insider directly owned 224,215 shares of the company’s stock, valued at approximately $2,908,068.55. This trade represents a 4.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 79,124 shares of company stock worth $1,038,364. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of REPL. BlackRock Inc. acquired a new stake in shares of Replimune Group during the second quarter worth approximately $99,171,000. Commodore Capital LP purchased a new position in Replimune Group during the fourth quarter valued at approximately $13,851,000. Opaleye Management Inc. acquired a new position in Replimune Group in the 2nd quarter valued at approximately $15,332,000. EcoR1 Capital LLC acquired a new position in Replimune Group in the 1st quarter valued at approximately $7,650,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Replimune Group in the 2nd quarter worth approximately $7,260,000. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.